MedTrace Logo

Extension Study of MYL-1701P-3001 for Safety and Efficacy

NCT04674800 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2022-08-26

No results posted yet for this study

Summary

This Study (AFIL-IJZ-3002) is designed to evaluate the safety, efficacy and immunogenicity of MYL-1701P among a group of participants successfully completing MYL-1701P-3001 study.

Conditions

Interventions

BIOLOGICAL

MYL-1701P, a proposed biosimilar to Eylea

Open label and single arm

Sponsors & Collaborators

  • Momenta Pharmaceuticals, Inc.

    collaborator INDUSTRY

  • Mylan Pharmaceuticals Inc

    lead INDUSTRY

Principal Investigators

  • Prasanna Ganapathi, MD · Mylan Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-23
Primary Completion
2022-04-20
Completion
2022-04-20
FDA Drug
Yes

Countries

  • India

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04674800 on ClinicalTrials.gov